



NDA 207947/S-005

**SUPPLEMENT APPROVAL**

Actelion Clinical Research  
Attention: Dana Leeds, PhD.  
Actelion Clinical Research, Inc.  
1820 Chapel Avenue West, Suite 300  
Cherry Hill, NJ 08002

Dear Dr. Leeds:

Please refer to your Supplemental New Drug Application (sNDA) dated and received November 15, 2017, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Upravi (selexipag) 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1000 mcg, 1200 mcg, 1400 mcg, and 1600 mcg Tablets.

This supplemental new drug application provides for the following change to the approved label as follows (additions are shown as underlined text and deletions are shown as strikethrough text):

1. Under **ADVERSE REACTIONS**, the following section as added:

**6.2 Postmarketing Experience**

The following adverse reactions have been identified during postapproval use of Upravi. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Symptomatic hypotension

2. The Contents section was updated to reflect the addition of Section 6.2.

**APPROVAL & LABELING**

We have completed our review of this supplemental application and it is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at

<http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

If you have any questions, please call:

Lori Anne Wachter, RN, BSN, RAC  
Regulatory Project Manager for Safety  
(301) 796-3975

Sincerely,

*{See appended electronic signature page}*

Mary Ross Southworth, PharmD.  
Deputy Director for Safety  
Office of Drug Evaluation I  
Center for Drug Evaluation and Research

ENCLOSURE(S):  
Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

MARY R SOUTHWORTH  
12/20/2017